Volume 23 - Issue 12 - December 2011

Predictive Value of SYNTAX Score in Risk Stratification of Patients Undergoing Unprotected Left Main Coronary Artery Angioplasty

Abstract: Background. The SYNTAX score is a useful tool to evaluate percutaneous coronary intervention risk regarding the number, complexity, and location of lesions. Despite its proven value in the prognosis of three-vessel disease, there are few data about its usefulness in other selected subsets of patients. This study aimed to evaluate the prognostic value of the SYNTAX score in a population of patients who underwent unprotected left main coronary artery (ULMCA) angioplasty in our hospital.

Predictors of Clinical SYNTAX Score in Coronary Artery Disease: Serum Uric Acid, Smoking, and Framingham Risk Stratification

Abstract: Background. High serum uric acid (SUA) has been well demonstrated to be associated with morbidity and mortality in the general population as well as in patients with coronary artery disease (CAD). Recent studies show that the clinical SYNTAX score (CSS) is a new tool for the risk stratification of patients with complex CAD. In this study, we aimed to evaluate whether SUA was associated with the complexity of CAD as evaluated by the CSS.

The SYNTAX Score Predicts Early Mortality Risk in the Elderly with Acute Coronary Syndrome Having Primary PCI

Abstract: Background. The SYNTAX score (SXscore), an angiographic score reflecting coronary lesion complexity, predicts clinical outcomes in patients with left main or multivessel disease, and in patients with ST-segment elevation myocardial infarction undergoing primary PCI. The clinical SXscore (CSS) integrates the SXscore and clinical variables (age, ejection fraction, serum creatinine) into a single score.

The SYNTAX Score: Usefulness, Limitations, and Future Directions

In 2009, the landmark Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial sought to establish whether coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) was the standard of care for patients with three-vessel or left main coronary artery disease.1

Percutaneous Closure of the Patent Ductus Arteriosus Using the Nit-Occlud PDA-R (Reverse) Device: Initial Experience Reporting Immediate and Short-Term Results

Abstract: Purpose. To review the initial clinical outcomes of patent ductus arteriosus (PDA) closure using the new Nit-Occlud PDA-R device (NOPDA-R). Materials and methods. The NOPDA-R is a self-expandable, nitinol-made, premounted and cone-shaped device with two distinctive features: reverse reconfiguration of the distal disc and a peculiar “snare-like” release mechanism. From May to December 2010, 20 consecutive patients were included.

Percutaneous Closure of Patent Ductus Arteriosus — Current Status

Since the description of successful surgical ligation of patent ductus arteriosus (PDA) by Gross and Hubbard in 1939,1 surgery has been the procedure of choice in the treatment of PDA. Surgical treatment has been shown to be safe and effective with only occasional complications. However, investigators have been attempting to develop less invasive, transcatheter methods to occlude the PDA.

30-Day Outcome After Percutaneous Coronary Angioplasty in Nonagenarians: Feasibility and Specific Considerations in Different Clinical Settings

Abstract: Background. Nonagenarians have been systematically excluded from randomized trials dealing with invasive coronary strategies, resulting in a lack of evidence-based guidelines regarding the optimal approach in this population. Aim. To describe the clinical and procedural characteristics and outcomes of patients 90 years of age or older who were treated with percutaneous coronary interventions (PCI).

Percutaneous Coronary Intervention in the Very Elderly: Do Nonagenarians Have the Most to Gain or the Most to Lose?

The elderly are often poorly represented in major clinical trials of percutaneous coronary intervention (PCI).1 An exact definition for “elderly” varies; for instance, the 2002 ACC/AHA practice guideline for the management of acute coronary syndromes considered patients ≥75 as a special “at-risk” group.2 Many clinical trials exclude patients over 75.

  • « Previous
  •  | Page 1 of 3 | 
  • Next »